Press for OvaScience

Cambridge-based OvaScience, which focuses on ways to treat infertility, announced today it has secured $37 million in Series B financing.

OvaScience, an innovative life science company dedicated to improving the treatment of infertility, today announced the appointment of Jeffrey D. Capello, executive vice president and chief financial officer of Boston Scientific (NYSE: BSX), to its board of directors.